# Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

> **NCT06625970** · PHASE3 · RECRUITING · sponsor: **UNICANCER** · enrollment: 700 (estimated)

## Conditions studied

- High Risk Prostate Carcinoma
- Prostate Cancer

## Interventions

- **DRUG:** Darolutamide
- **RADIATION:** Stereotactic Body RadioTherapy (SBRT)
- **DRUG:** ADT (Standard of Care)
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT06625970
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-10
- **Primary completion:** 2033-10
- **Final completion:** 2045-10
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2025-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06625970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06625970, "Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06625970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*